OncoMatch/Clinical Trials/NCT03118986
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
Is NCT03118986 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Olanzapine for vomiting in infants and/or children.
Treatment: Olanzapine — Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy
Check if I qualifyExtracted eligibility criteria
Lab requirements
Kidney function
Plasma creatinine within 1.5 times the upper limit of normal for age
Liver function
Plasma conjugated bilirubin ≤ 3x upper limit of normal for age unless attributable to Gilbert's Syndrome; ALT ≤ 5x upper limit of normal for age
Cardiac function
Baseline ECG within the month prior to study drug administration without known clinically significant abnormalities including pathologic prolongation of QTc
Plasma creatinine within 1.5 times the upper limit of normal for age. Amylase within age-appropriate limits. Plasma conjugated bilirubin ≤ 3x upper limit of normal for age unless attributable to Gilbert's Syndrome. ALT ≤ 5x upper limit of normal for age. Baseline ECG within the month prior to study drug administration without known clinically significant abnormalities including pathologic prolongation of QTc
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California · San Francisco, California
- The Children's Mercy Hospital · Kansas City, Missouri
- Columbia University/Morgan Stanley Children's Hospital · New York, New York
- University of North Carolina at Chapel Hill · Chapel Hill, North Carolina
- Nationwide Children's Hospital · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify